Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Divalproex Sodium,Sodium Valproate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Cereno's HDAC Inhibitor Reduces Risks from PAH in Phase 2 Trial
Details : CS1 is an HDAC inhibitor that works through epigenetic modulation, being developed as a safe, effective and disease modifying treatment for pulmonary arterial hypertension.
Brand Name : CS1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 30, 2024
Lead Product(s) : Divalproex Sodium,Sodium Valproate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : CS585
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : University of Michigan
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Preclinical data from drug candidate CS585 demonstrating that it targets the IP receptor for prevention of thrombosis without increased risk of bleeding.
Brand Name : CS585
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 09, 2022
Lead Product(s) : CS585
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : University of Michigan
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : CS1
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH.
Brand Name : CS1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 17, 2021
Lead Product(s) : CS1
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?